Riskpilot← Back to searchSign inGet full accessPHARMANOVA AS
ASActiveOrg 999566650Bøveien 510, 8470 Bø I VesterålenRetail sale of other food · NACE 4727Est. 20130 employees
Revenue 2024
NOK 18,5M
+216% vs 2023
EBITDA margin
7.3%
+747% vs 2023
Equity ratio
30.8%
Financial strength
Net profit 2024
NOK 1,3M
+470% vs 2023
| Revenue | NOK 18,5M | +216% |
| EBITDA | NOK 1,3M | +747% |
| Net profit | NOK 1,3M | +470% |
| Total assets | NOK 10,3M | +27% |
| Equity | NOK 3,2M | +66% |
| Employees | 0 | — |
Legal name
PHARMANOVA AS
Org number
999566650
Legal form
Aksjeselskap
NACE code
4727 · Retail sale of other food
Founded
22. januar 2013
Share capital
NOK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Salg av kosttilskudd, helsekost- og kosmetikkprodukter - samt andre produkter som naturlg faller sammen med dette, samt investeringer og konsulenttjenester - herunder delta i andre selskaper med lignende virksomhet.
Address
Bøveien 510, 8470 Bø I Vesterålen
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 066 | 10 601 | 16 926 | 15 639 | 8 859 | 4 657 | 3 599 | 3 037 | 3 684 | 2 589 | 5 833 | 18 457 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −372 | 4 384 | 7 538 | 6 424 | 5 164 | 3 098 | 2 011 | 1 151 | −460 | −148 | 159 | 1 347 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −6 |
| EBIT | −372 | 4 384 | 7 538 | 6 424 | 5 164 | 3 098 | 2 011 | 1 151 | −460 | −148 | 159 | 1 341 |
| Net financials | 0 | 1 | 38 | 227 | 15 | 2 | 11 | 5 | −16 | 36 | 63 | 183 |
| Profit before tax | −372 | 4 385 | 7 576 | 6 651 | 5 179 | 3 100 | 2 022 | 1 156 | −475 | −112 | 222 | 1 524 |
| Tax | −102 | 1 184 | 2 036 | 1 596 | 1 243 | 713 | 445 | 254 | 1 | −2 | −0 | 257 |
| Net profit | −270 | 3 201 | 5 540 | 5 055 | 3 936 | 2 387 | 1 577 | 902 | −477 | −110 | 222 | 1 267 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 150 | 4 812 | 9 102 | 9 322 | 7 105 | 4 217 | 5 211 | 3 671 | 2 293 | 2 298 | 8 156 | 10 329 |
| Equity | −176 | 100 | 100 | 100 | 100 | 2 487 | 2 075 | 2 277 | 1 800 | 1 691 | 1 913 | 3 180 |
| Long-term debt | 0 | 7 | 31 | 17 | 2 | 1 | 1 | 1 | 2 | 0 | 0 | 257 |
| Short-term debt | 1 326 | 4 705 | 8 971 | 9 204 | 7 003 | 1 729 | 3 135 | 1 393 | 491 | 608 | 6 243 | 6 892 |
| Total debt | 1 326 | 4 712 | 9 002 | 9 222 | 7 005 | 1 730 | 3 136 | 1 394 | 493 | 608 | 6 243 | 7 149 |
EBITDA margin
7.3%
This company
15.8%
Market median
-54% vs market
20132024
Equity ratio
30.8%
This company
38.2%
Market median
+19% vs market
20132024
Return on equity
39.8%
This company
18.4%
Market median
+116% vs market
20132024
Net profit margin
6.9%
This company
8.1%
Market median
-15% vs market
20132024
Asset turnover
1.79×
This company
1.12×
Market median
+60% vs market
20132024
Debt / equity
2.25×
This company
0.62×
Market median
-263% vs market
20132024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
IL Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2013 | — | — | |
| Board of Directors | 2013 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Global Pharma Group As | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Global Pharma Group As
PHARMANOVA AS Board members of PHARMANOVA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ivar Larsen Fjeldberg | Chief Executive Officer | 0 companies |
| Tom Bjarte Norland | Board of Directors | 0 companies |
| Odd-Arne Landevåg | Board of Directors | 0 companies |
| Henrik Rødsand | Chairman | 0 companies |
| Henrik Hallstein Rødsand | Chairman | 0 companies |
| Thomas Kristoffer Storvestre | Chairman | 0 companies |